Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.

Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.

Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). The polypeptide heterodimer comprises two or more binding domains that specifically bind one or more targets (e.g., a receptor). In addition, both chains of the heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in directing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.

Abstract: The present disclosure provides polypeptide heterodimers formed between two different single chain fusion polypeptides via natural heterodimerization of an immunoglobulin CH1 region and an immunoglobulin light chain constant region (CL). One chain of a heterodimer comprises a binding domain that specifically binds a target (e.g., a receptor). In addition, both chains of a heterodimer further comprise an Fc region portion. The present disclosure also provides nucleic acids, vectors, host cells and methods for making polypeptide heterodimers as well as methods for using such polypeptide heterodimers, such as in reducing T cell activation, inhibiting solid malignancy growth, and treating autoimmune or inflammatory conditions.

Abstract: This disclosure provides immunoglobulin binding molecules that specifically bind to human macrophage stimulating receptor (MST1 R, also referred to herein as recepteur d'origine Nantaise or RON), including antibodies and monospecific and multispecific single chain binding proteins having one or more other domains, such as one or more antibody constant region domains. Also provided are therapeutic applications of such binding proteins, such as for the treatment of cancer and inflammatory disorders.

Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.

Abstract: This disclosure provides a multi-specific fusion protein composed of a CD86 antagonist binding domain and another binding domain that is an IL-10 agonist, an HLA-G agonist, an HGF agonist, an IL-35 agonist, a PD-1 agonist, a BTLA agonist, a LIGHT antagonist, a GITRL antagonist or a CD40 antagonist. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Abstract: Single chain fusion proteins that specifically bind to a TCR complex or a component thereof, such as TCR?, TCR?, or CD3?, along with compositions and methods of use thereof are provided.

Abstract: The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.

Abstract: This disclosure provides a multi-specific fusion protein composed of a CD72-ligand binding domain and another binding domain specific for a heterologous target, such as a B-cell specific protein. The multi-specific fusion protein may also include an intervening domain that separates the other domains. This disclosure also provides polynucleotides encoding the multi-specific fusion proteins, compositions of the fusion proteins, and methods of using the multi-specific fusion proteins and compositions.

Abstract: Connector apparatus, and an associated method, by which to apply electrical power to a set of consumer electronic devices, such as a laptop computer and a mobile phone, or other portable device. The connector includes an input port to which a source of input power is applied, such as the electrical power provided by way of a power cable of the laptop computer, once suitably connected to a source of permanent electric power. The connector apparatus includes a set of output ports, a first port of which is connectable to the laptop computer and a second port of which is connectable to the other portable electronic device. A user of the consumer electronic devices is able thereby to power both of the devices with connection of only a single power cable to a permanent power supply source.

Abstract: The present invention provides methods for identifying agents useful for inhibiting cancer cells by binding to various nuclear receptor proteins, or to the genes or RNA encoding such proteins.

Abstract: The present invention is directed to methods of identifying agents useful for inhibiting cancer cells. The agents bind to one of the proteins described herein, or to a gene or mRNA encoding such protein. The invention is also directed to methods for inhibiting cancer cells by administering an agent that binds to one of the proteins described herein, or to a gene or mRNA encoding such protein.

Abstract: Connector apparatus, and an associated method, by which to apply electrical power to a set of consumer electronic devices, such as a laptop computer and a mobile phone, or other portable device. The connector includes an input port to which a source of input power is applied, such as the electrical power provided by way of a power cable of the laptop computer, once suitably connected to a source of permanent electric power. The connector apparatus includes a set of output ports, a first port of which is connectable to the laptop computer and a second port of which is connectable to the other portable electronic device. A user of the consumer electronic devices is able thereby to power both of the devices with connection of only a single power cable to a permanent power supply source.

Abstract: A three-dimensional system for simulating the life cycle of enterprise alliance is described. The system and method are actualized as a matrix correlating business strategy and alliance benefit payoff and further mapped onto an axis of strategic structural scenarios. By providing basic financial information of an enterprise, one can determine where the enterprise is in relation to its expected life cycle. More importantly, the same system and method also show graphically and analytically what an enterprise has to do to achieve the next level of performance in a possible strategic alliance.

Abstract: The present invention is a novel method simulating and managing an alliance investment portfolio. It begins with the rationalization and creation of select alliances to become assets of an investment portfolio. The assets are categorized into a matrix combination of nine different financial variations that respond to the iterative nature of investment dynamics. Each of the select alliance is subjected to a ball and prism test determining the sustainability of growth of such alliance within the investment portfolio. Finally, the liquidity to be provided by investors to a vertical axis through the center of matrix combination of nine different financial variations in creating spatial representation of liquidity ad leverage relationship for alliance investments. Through the 3×3×3 alliance mix representation, one could derive valuation, pricing and other portfolio management information for alliance portfolio transparently and dynamically.